The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2018 | Venetoclax and bendamustine plus rituximab or obinutuzumab for CLL
Stephan Stilgenbauer, MD, of the University of Ulm, Ulm, Germany, speaks at the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA. He discusses the the results of the Phase Ib GO28440 study (NCT01671904) looking at the safety and efficacy of venetoclax in combination with bendamustine plus rituximab or obinutuzumab in patients with previously untreated or relapsed/refractory chronic lymphocytic leukemia (CLL). He describes the high response rates, MRD outcomes and toxicity profile of this combination.
